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Au nanoparticles have been used in biomedical applications since ancient times. However, the rapid development of nano-
technology over the past century has led to recognition of the great potential of Au nanoparticles in a wide range of applica-
tions. Advanced fabrication techniques allow us to synthesize a variety of Au nanostructures possessing physiochemical prop-
erties that can be exploited for different purposes. Functionalization of the surface of Au nanoparticles further eases their ap-
plication in various roles. These advantages of Au nanoparticles make them particularly suited for cancer treatment and diag-
nosis. The small size of Au particles enables them to preferentially accumulate at tumor sites to achieve in vivo targeting after 
systemic administration. Efficient light absorption followed by rapid heat conversion makes them very promising in photo-
thermal therapy. The facile surface chemistry of Au nanoparticles eases delivery of drugs, ligands or imaging contrast agents in 
vivo. In this review, we summarize recent development of Au nanoparticles in cancer theranostics including imaging-based 
detection, photothermal therapy, chemical therapy and drug delivery. The multifunctional nature of Au nanoparticles means 
they hold great promise as novel anti-cancer therapeutics.   
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Cancer is a major public health problem globally. Accord-
ing to the American Cancer Society, over 1.6 million new 
cancer cases and 0.6 million deaths from cancer were pro-
jected to occur in the United States alone in 2011 [1]. Thus 
there is an urgent need for novel anti-cancer therapeutics. 
Nanoparticles, as an extension of nanotechnology, have 
shown potential in multiple applications including cancer 
treatment [2]. Gold (Au) nanoparticles are one of the most 
promising candidates for cancer treatment because of their 
unique physiochemical properties. This review will focus on 
recent advances of the use of Au nanoparticles in cancer 
theranostics including imaging-based detection, photother-
mal therapy, chemical therapy and drug delivery. 
1  Au nanoparticles––a brief history and their 
biocompatibility 
Colloidal Au nanoparticles were discovered by Faraday in 
1857, when he observed a range of colors originating from 
some unidentified particles in a gold chloride solution after 
adding reducing and stabilizing agents [3]. In 1908, Mie 
explained the intense colors in Faraday’s gold solution by 
solving Maxwell’s electromagnetic equation, concluding the 
phenomenon was related to the absorption and scattering of 
light by gold nanospheres present in the solution [4]. With 
the advent of the electron microscope in 1932 [5], different 
nanostructures formed under varying synthetic conditions 
could be studied systematically, resulting in the rapid de-
velopment of methodology to prepare nanostructures. There-
after, a range of Au nanostructures (Figure 1) were synthe-
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sized, and chemical conditions were optimized [6–12]. The 
size, shape and surface chemistry of Au nanoparticles were 
also controlled to produce nanoparticles suitable for differ-
ent purposes [13].  
Biocompatibility is essential and is systemically evalu-
ated before chemical structures are used in clinical experi-
ments. It is well known that current anti-cancer drugs pro-
duce severe side effects because of their strong cytotoxicity 
and poor targeting. In contrast, Au nanoparticles are con-
sidered to be relatively safe, a view supported by most in 
vitro studies to date. Elemental Au is highly inert, so direct 
chemical interaction with biomolecules can be minimized. 
However, potent catalytic activity arising from the large 
relative surface area of small particles (several nm) [14,15], 
and additional agents present in Au nanoparticles [1618] 
are reported to be hazardous in some cases. Recently, Qiu 
and co-workers [19] from our group have demonstrated 
coating molecule-dependent cytotoxicity using Au nanorods. 
Different coating agents, cetyltrimethylammonium bromide 
(CTAB), polystyrene sulfonate (PSS) and polydiallyldime-
thyl ammonium chloride (PDDAC), were systemically 
studied. It was found that CTAB-coated Au nanorods in-
duced a cytotoxic effect in human breast cancer cell line 
MCF-7 (Figure 2), resulting in apoptosis and cell cycle ar-
rest, but PSS and PDDAC-coated ones did not. Later, Wang 
et al. [20] from our group further showed that the intracel-
lular presence of free CTAB molecules could break lyso-
some membrane integrity and lead to accumulation of Au 
nanorods released from lysosomes in mitochondria, which 
eventually caused mitochondrial dysfunction-mediated cell 
death. These results stress the importance of the surfactant 
CTAB in Au nanorod-induced cytotoxicity. However, such 
undesired side effects can be avoided simply by changing 
the capping agent. The flexible synthetic conditions of Au 
nanoparticles mean that materials suitable for biomedical 
applications are a realistic possibility. 
2  Au nanoparticles in cancer diagnosis –– im- 
aging-based detection 
Au has been expensive since historic times because of its 
rarity, stability and brilliant colors. In the past, people made 
use of the brilliant colors of Au in stained glass and decora-
tive artworks. In modern times, people learned the reason 
for these brilliant colors and developed novel strategies to 
exploit the unique optical properties of Au in biomedical 
applications including biosensing and imaging. 
Faraday was the first to attribute the bright colors of 
some Au solutions to colloidal Au [3], and Mie [4] ex-
pounded the origin of this phenomenon by solving Max-
well’s electromagnetic equation for the interaction of light 
with spherical particles. For a spherical nanoparticle much 
smaller than the wavelength of light (diameter d ), an 
electromagnetic field at a certain frequency (v) induces a 
resonant oscillation of the metal-free electrons across the 
nanoparticle. This oscillation is known as surface plasmon 
resonance (SPR) [21–23]. The surface plasmon oscillation 
of the metal electrons results in a strong enhancement of 
absorption and scattering of electromagnetic radiation in  
 
 
Figure 1  Au nanoparticles of various size and shape with potential applications in biomedicine. A–D, Au nanorods with different aspect ratios. E, Au 
nanospheres. F, Au nanostars. G, Au nanoboxes. H, Au nanocages. I, Hollow Au nanospheres. J, Au nanocubes. K, Au nanocrystals. L, Au obtuse triangular  
bipyramids. Adapted from ref. [8–12,19] with permission from the American Chemical Society and Elsevier. 
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Figure 2  Cytotoxicity studies using a human breast cancer line MCF-7 treated with Au nanoparticles coated with CTAB, PSS and PDDAC. A, CCK-8 
assays illustrating cell viability after 24, 48, or 72 h of treatment with Au nanoparticles with different coatings. B, TEM images of cells incubated with 
CTAB-coated Au nanoparticles. Most Au nanoparticles appeared to be within the lysosome initially, whereas some were observed in the mitochondria 
thereafter. C, Mitochondrial damage caused by Au nanoparticles coated with CTAB. The probe molecule JC-1 emits red fluorescence when the mitochondri-
al membrane potential is normal and turns green as the reactive oxygen species (ROS) level increases through oxidative stress caused by mitochondria dam- 
age. Scale bar, 10 mm. Reproduced with permission from ref. [19]. 
 
resonance with the SPR frequency of the Au nanoparticles, 
giving them intense colors and interesting optical properties 
[24]. The frequency and cross-section of SPR absorption 
and scattering is dependent on the metal composition [25], 
nanoparticle size and shape [26], dielectric properties of the 
medium/substrate [27] and presence of interparticle interac-
tions [28]. These factors provide much room for Au nano-
particles to adjust their SPR performance to suit the re-
quirements of different applications. Meanwhile, any varia-
tion in SPR performance reveals corresponding information 
related to changes in the Au nanoparticles, thus enabling 
them to be developed as sensors that can detect the local 
refractive index/dielectric constant of the environment sur-
rounding the nanoparticles [29]. The SPR of nanospheres 
shifts to longer wavelength as the refractive index of the 
medium increases [25]. This phenomenon has been ex-
ploited in the sensing of biomolecular analytes by monitor-
ing the changes in the SPR wavelength following adsorp-
tion/binding events at the surface of Au nanoparticles [30]. 
The SPR of Au nanoparticles can also be red-shifted by the 
self-assembly or aggregation of particles [31]. 
Besides showing great potential as biosensors, the appli-
cation of Au nanoparticles in cancer diagnosis has mainly 
focused on cancer cell imaging-based detection. There are 
four major types of imaging using Au nanoparticles, in-
cluding light scattering imaging, two-photon fluorescence 
(TPF) imaging, photoacoustic imaging and X-ray computed 
tomography (CT).  
2.1  Light scattering imaging 
Light scattering imaging originates from the significant 
SPR-based light scattering capability of Au nanoparticles at 
their plasmon wavelengths [32]. Compared with emission 
from fluorescent dye molecules, the scattering cross-sec-      
tions of Au nanoparticles could provide stronger photon 
intensity by more than five orders of magnitude [33]. Thus, 
high-contrast images are attainable as long as the Au nano-
particles accumulate only within cancer cells. To date, most 
studies used immune-targeting to localize Au nanoparticles 
in the desired region. Sokolov and co-workers [34] conju-
gated anti-epidermal growth factor receptor (EGFR) anti-
bodies to colloidal Au nanoparticles with a diameter of 12 
nm via noncovalent electrostatic adsorption. Emission from 
the nanoparticles was observed inside cervical cancer cell 
line SiHa, which overexpressed EGFR at the cell membrane, 
under dark-field monochromatic light illumination. In con-
trast, Au nanoparticles conjugated with bovine serum albu-
min molecules were not observed on the dark background, 
which illustrated the necessity of antibody-mediated target-
ing for cancer cell imaging. Another representative work 
was conducted by Huang et al. [35]; they used white light as 
an excitation source and observed strong light scattering 
from Au nanorods in the near-infrared (NIR) region. After 
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conjugation with anti-EGFR antibodies, Au nanorods selec-
tively accumulated in two malignant epithelial cell lines 
(human oral squamous carcinomas, HSC and HOC) but not 
in a benign cell line (HaCaT). The Au nanorods in HSC and 
HOC cells were visualized on a dark background (Figure 3). 
Currently, dark-field imaging based on the light scattering 
properties of Au nanoparticles is widely used for cancer 
imaging through functionalized nanoparticle-receptor bind-
ing to cell surface biomarkers [36,37].  
2.2  Two-photon fluorescence (TPF) imaging 
TPF is another advantage of Au nanoparticles (especially 
Au nanorods) that can be used to visualize target cells or the 
particles themselves. TPF, also called two-photon lumines-
cence, refers to the stronger luminescence emitted by na-
noscale materials than their bulk form [38] (e.g., the quan-
tum yield of emission of Au nanorod is 6–7 orders of mag-
nitude larger than that of bulk gold [39]). Under femto-
second NIR laser excitation, enhanced TPF is able to pro-
duce very strong signals, even allowing single nanoparticles 
to be detected [39]. Durr and co-workers [40] explored the 
capability of TPF imaging in a 3D tissue model using Au 
nanorods conjugated with antibodies to target cancer cells 
embedded in the collagen matrices. The TPF signals of Au 
nanorods are three orders of magnitude stronger than the 
autofluorescence from the surrounding tissues, so in cancer 
cell imaging with a spatial resolution of 75 µm was attained. 
Tong et al. [41] tracked the cellular uptake of Au nanorods 
conjugated with a folate ligand in KB cancer cells, which 
overexpress folate receptors, and NIH-3T3 normal fibro-
blasts using TPF. The localization of Au nanorods after dif-
ferent periods was sharply visualized, illustrating lig-
and-receptor binding-mediated endocytosis. 
2.3  Photoacoustic imaging 
Photoacoustic imaging is a new combinational imaging 
method. It uses a laser as an excitation source and acoustic 
waves as the detection target, and requires the application of 
a specific material as a linker. This material needs to be able 
to absorb light and convert it into heat, which leads to ther-
mal expansion of the air surrounding the material, creating 
acoustic waves for imaging. Au nanoparticles are ideal can-
didates for photoacoustic imaging because of their 
SPR-based light absorption. SPR leads to both light absorp-
tion and scattering enhancement [24], so relatively large 
nanoparticles are preferred because they possess higher ab-
sorption/scattering ratios [42]. Li and co-workers [43] 
demonstrated photoacoustic imaging in vivo using Au na-
norods conjugated with antibodies targeting cancer cells. 
The contour of the tumor region was sharply visualized in 
fusion images acquired from photoacoustic and ultrasound 
signals. Antibody-mediated targeting was found to be es-
sential for such in vivo tumor visualization because images 
were not obtained at the tumor sites of mice injected with 
Au nanorods alone. The intensity of the photoacoustic sig-
nal was time dependent and reached a maximum at 7 h post 
injection.   
2.4  X-ray computed tomography 
Au nanorods also readily absorb X-rays. Based on this 
property, Bahatia et al. [44] developed a three-dimen-      
sionally reconstructed tumor xenograft model using X-ray 
CT and the contrast from tumor-accumulated Au nanorods 
(Figure 4A). Under the guidance of this model, they 
achieved complete tumor regression in mice treated with 
PEGylated Au nanorods following computationally tailored 
irradiation (810 nm, 2 W cm2, 5 min) (Figure 4B). 
3  Au nanoparticles in cancer therapy 
3.1  Photothermal contrast agents 
Plasmonic photothermal therapy (PPTT) is the most prom-
ising application of Au nanoparticles in cancer treatment 
[4448]. The ability of Au nanoparticles to efficiently ab-
sorb light followed by rapid heat conversion makes them a 
suitable candidate for cancer hyperthermia treatment. In 
addition, Au nanoparticles are not susceptible to photo-
bleaching [49], and their optical absorption can be easily 
tuned by changing their size and shape [21,33]. As a result,  
 
 
Figure 3  Light scattering and TPF images of different cells. A and B, Dark-field images of Au nanorods conjugated with anti-EGFR antibodies. For cancer 
cell line HOC (B), which overexpresses EGFR, the cell morphology was clearly visualized because of the accumulation of Au nanorods, whereas the cell 
morphology of normal cell line HaCaT (A) is not recognized because of nonspecific binding. C, Confocal image of HeLa cells in the presence of Au nano-
rods (blue, nuclei; red, actin cytoskeleton; green, Au nanorods). This image was taken by two-photon microscopy. Reproduced with permission from  
ref. [35,39]. 
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Figure 4  In vivo and in vitro plasmonic photothermal therapy (PPTT) using Au nanoparticles. A, PEGylated Au nanorods were added intratumorally to 
mice with bilateral MDA-MB-435 tumors and imaged using X-ray CT to visualize the three-dimensional distribution of nanoparticles in the tumors (left). A 
three-dimensional solid model of the complete geometry was rapidly reconstructed by image processing for use with computational photothermal modeling 
(middle; red, PEGylated Au nanorods). Experimental thermographic surveillance of NIR irradiation after X-ray CT (0.75 W cm2, 1 min; right). B, Mice 
harboring MDA-MB-435 human tumors were injected with either saline or PEGylated Au nanorods. 72 h post injection, the flank of each mouse was ex-
posed to a computationally designed irradiation regimen (810 nm, 2 W cm2, 5 min). Plots of tumor volume (left) and long-term survival (right) over time 
after irradiation are also shown. C, Cellular ablation achieved using bare Au/Au sulfide nanoparticles with laser irradiation. The yellow circle indicates the  
laser spot; live/dead stain for viability shows dead cells as red while viable cells appear green. Reproduced with permission from references [44,60]. 
the electromagnetic spectrum of Au nanoparticles can be 
red-shifted to the NIR region, which allows high-depth 
PPTT in tissues [50]. Jain et al. [33] used Mie theory and 
the discrete dipole approximation method to calculate the 
absorption and scattering efficiencies and optical resonance 
wavelengths of three typical classes of nanoparticles: Au 
nanospheres, silica-Au nanoshells, and Au nanorods. Au 
nanoshells were found to have optical cross-sections com-
parable to or higher than nanospheres. The optical reso-
nance of the nanorods could be linearly tuned across the 
NIR region by changing either their effective size or aspect 
ratio. Au nanorods show per micron absorption and scatter-
ing coefficients that are an order of magnitude higher than 
those of nanoshells and nanospheres. While nanorods with a 
higher aspect ratio and smaller effective radius are the best 
photoabsorbing nanoparticles, the highest scattering contrast 
for imaging applications is obtained from nanorods with a 
high aspect ratio and a larger effective radius [33]. 
Compared with conventional agents used in laser photo-
thermal tumor therapy (e.g., indocyanine green, and naph-
thalocyanines), there are several distinct advantages of Au 
nanoparticles: (i) higher absorption cross-section because of 
their enhanced SPR effect (five orders of magnitude larger 
than indocyanine green for nanospheres with a diameter of 
40 nm and an absorption band around 530 nm) [49,51]; (ii) 
deep tissue penetration of up to a few centimeters after the 
“NIR window” shift using the tunable optical extinction of 
Au nanoparticles; (iii) facile bioconjugation with various 
molecules (e.g., peptides, proteins and DNA) [52,53], ena-
bling multi-targeting in a single treatment.  
PPTT using Au nanoparticles was first demonstrated by 
Lin and co-workers in 2003 [54]. This method exploits the 
unique ability of noble metal nanoparticles (e.g., Au, Ag, 
and Cu nanoparticles) to efficiently absorb photons through 
SPR [55], which distinguishes them from traditional photo-
absorbing agents such as chromophores and dye molecules. 
Subsequently, a number of Au nanostructures including na-
norods, Au-silica nanoshells, nanocages, hollow nanoshells 
and Au-Au sulfide nanoparticles have been synthesized and 
used in both in vitro and in vivo cancer hyperthermia re-
search [54–62]. 
The first gold nanostructure employed for PPTT was 
spherical Au nanoparticles. Following conjugation to IgG, 
which targets the CD8 receptor on peripheral blood lym-
phocyte cells, Lin et al. [54] found 95% of cells containing 
as few as ca. 500 nanoparticles per cell were killed (versus 
5%8% in a control treatment) after exposure to a nano-
second pulsed visible laser. Later, researchers from the 
El-Sayed group [56] demonstrated selective PPTT using 
spherical Au nanoparticles with a diameter of 40 nm conju-
gated to EGFR IgG. Cancer cell-targeting mediated by 
EGFR antibody allowed Au nanoparticles to specifically 
accumulate around/within HSC and HOC human oral 
squamous cell lines after 30 min incubation compared with 
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in a benign cell line (HaCaT). Intense SPR scattering of Au 
nanoparticles under white light excitation on a dark back-
ground confirmed the difference of accumulation in the 
various types of cells. Using a continues wave argon ion 
laser at 514 nm, the two cancer cell lines suffered severe 
photothermal damage within 4 min at laser energy thresh-
olds of 19 and 25 W cm2, which were less than half that of 
the benign cells (57 W cm2). This selective killing of can-
cerous cells combined with the high absorption cross-section 
of the Au nanoparticles eases photothermal cancer therapy 
at sufficiently low laser energy that the benign cells remain 
undamaged.  
The in vitro success of cancer therapy using visible 
light-absorbing Au nanoparticles can be extended to skin or 
surface cancer. However, deep tissue penetration is not pos-
sible with visible light [50], so tuning the SPR absorption 
band of Au nanoparticles to the “NIR window” is required 
to extend their use to cancer in deep tissues. 
Halas and co-workers [57] used Au nanoshells (silica 
core with a diameter of 55 nm, and a 10 nm-thick Au shell) 
in NIR PPTT. By varying the relative core and shell thick-
ness of the Au nanoshells, their SPR absorption was varied 
across a broad range of wavelengths that extended from the 
visible to the NIR region. Breast carcinoma cells labeled 
with PEGylated Au nanoshells that showed SPR centered at 
800 nm suffered notable photothermal damage after expo-
sure to NIR laser light (820 nm, 4 W cm2, 7 min). Subse-
quently, systemic administration of these Au nanoshells to a 
colon cancer model was conducted by the same group to 
evaluate their efficacy in NIR PPTT in vivo [57]. PEGylated 
Au nanoshells were intravenously injected and tumors re-
ceived NIR laser radiation 6 h post passive accumulation (4 
W cm2, 3 min). Tumors in mice treated with Au nanoshells 
exhibited complete regression after a single PPTT treatment, 
and the animals were tumor free after 90 d. In contrast, tu-
mors in the control group continued to grow, which led to a 
mortality of almost 50% after just 10 d. El-Sayed and 
co-workers later demonstrated the effectiveness of Au na-
norods in NIR PPTT both in vitro [35] and in vivo [58]. 
Unlike Au nanoshells, Au nanorods are smaller, so the 
“NIR window” shift can be easily obtained based on the 
plasmon oscillation of electrons along the longitudinal axis 
of the nanorods [59]. In a tumor-bearing mice model, 
PEGylated Au nanorods accumulated efficiently and exhib-
ited enhanced NIR absorption at the tumor site following 
intravenous administration. After a single NIR laser radia-
tion (2 W cm2, 10 min), 25% of the tumors in treated mice 
were completely resorbed at day 13 [58]. West et al. [60] 
realized NIR PPTT using Au-Au sulfide nanoparticles. The 
biggest advantage of this nanostructure is that its absorp-
tion/scattering ratio (98%2%) is higher than those of other 
nanostructures like Au-silica nanoshells (70%30%). In 
their experiment, human prostate cancer cell line PC3 was 
efficiently ablated in vitro after laser irradiation (Figure 4C) 
and more than 80% of mice that received PPTT remained 
alive 8 weeks after treatment. 
Overall, the unique SPR effect of Au nanoparticles 
makes them highly potent in photothermal cancer therapy. 
In addition, the easy modification of Au nanostructures 
means their intrinsic properties can readily be adapted to 
suit different applications. 
3.2  Antineoplastic activity 
The SPR-based optical properties of Au nanoparticles [61] 
have directed much attention toward their development as 
novel contrast agents in photothermal cancer therapy 
[48,62]. However, another typical characteristic of Au na-
noparticles is that they are of comparable size to biomole-
cules, ranging from several to hundreds of nanometers. This 
resemblance provides great opportunities for them to di-
rectly interact with biomolecules such as proteins, lipids, 
and nucleic acids, so they can be used to regulate cellular 
behaviors.  
Malignant cells display several characteristics including 
reliance on mitogenic signals and abnormal energy metabo-
lism [63] that are different from normal cells, which make 
them quite vulnerable to particular treatments like hyper-
thermia. Recently, we demonstrated a cancer cell-specific 
inhibitory effect using Au nanorods coated with serum pro-
tein [20]. The cell viability of human pulmonary carcinoma 
cell line A549 was found to be severely inhibited (Figure 
5A), while normal bronchial epithelial cell line 16HBE and 
primary adult stem cell MSC exhibited little cytotoxicity 
after incubation with Au nanorods at the same concentration. 
Intracellular trafficking of Au nanorods was investigated 
using TEM. A marked dissimilarity was observed in the 
distribution patterns in A549 and 16HBE/MSC. Au nano-
rods selectively entered the mitochondria in cancer cell line 
A549 but not in 16HBE and MSC cells, although most of 
the Au nanorods appeared to be trapped in the lysosomes 
initially in all three types of cells. The assembly of Au na-
norods in mitochondria further led to a series of pathologi-
cal changes to this organelle including swollen morphology 
and partial disappearance of crista. In the end, the shape of 
the A549 cells was changed significantly (Figure 5B), and 
apoptosis-like characteristics were observed. The mecha-
nism of Au nanorod translocation from lysosome to mito-
chondria specifically in the A549 cells was thought to be 
related to an interaction between Au nanorods and lysosome 
membrane that resulted in leakage of the nanorods (Figure 
5C), and finally determined the fate of A549 cells. This 
work introduced a novel anti-cancer strategy using Au na-
norods as a mitochondrial targeting agent to selectively kill 
cancer cells because of the different responses of the lyso-
some membranes in cancer and normal cells to Au nanorods 
(Figures 5C and D).  
Besides a mitochondrial targeting-induced cytotoxic ef-
fect, it has been reported that Au nanoparticles can be used  
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Figure 5  CTAB-coated Au nanorods were able to selectively kill cancer cells. A, Cell viability in A549 determined by CCK-8 after exposure to Au nano-
rods. B, Shrinkage in cytoskeleton (stained by rhodamine-labeled phalloidin) was observed in A549, but not in 16HBE cells treated with Au nanorods for 24 
h. C, Mitochondrial membrane potentials and the integrity of lysosomal membrane were severely damaged by Au nanorods only in A549 cells (as indicated 
by varied fluorescent colors in JC-1 probe and decreasing red fluorescence of AO probe). D, Possible mechanism of cell damage. Reproduced with  
permission from ref. [20]. 
to treat neoplasia. The underlying mechanisms of this 
treatment involve cell cycle regulation [64], DNA-targeted 
damage [66], anti-angiogenesis [65,67] and oxidative stress 
[68].  
New blood vessel formation (also called angiogenesis) is 
required for cancer to develop from cells into tissue. Thus 
anti-angiogenesis is considered to be an effective method to 
treat neoplasia. Mukhopadhyay and co-workers [65] inves-
tigated the influence of spherical Au nanoparticles with a 
diameter of 5 nm on human umbilical vascular endothelial 
cells (HUVEC). The Au nanoparticles significantly inhibit-
ed the VEGF-165-induced cell proliferation of HUVEC by 
directly binding to the heparin-binding domain of 
VEGF-165 via sulfur and/or nitrogen bonds. This interac-
tion severely hindered the normal biological process in-
volving association of VEGF-165 with cell membrane re-
ceptors, which is necessary for self-proliferation and angio-
genic signaling transduction. Subsequently, they showed the 
binding interaction was highly specific because the Au na-
noparticles did not affect the signaling/proliferation associ-
ated with another non-heparin-binding growth factor, 
VEGF-121. The group later investigated the anti-angiogenic 
effect of Au nanoparticles in an ovarian tumor-bearing nude 
mice model and achieved results consistent with in vitro 
findings. This research is intuitively associated with an an-
tibody-based regimen (e.g., avastin, an antibody that binds 
specifically to vascular endothelial growth factor receptors 
(VEGFRs) in a clinical setting because they possess similar 
functions. More nanostructures like this need to be designed 
and developed to offer some alternatives in antibody-       
mediated cancer therapy.  
Interference with mitogenesis is another strategy in 
which Au nanoparticles can be exploited in anti-cancer 
therapies. Xing et al. [64] examined the regulatory effects 
of glucose-capped Au nanoparticles with a diameter of 10.8 
nm in the cell cycle in human prostate carcinoma cell line 
DU-145. The glucose-Au nanoparticles arrested the cell 
cycle of DU-145 cells in the G2/M phase through upregula-
tion of the expression of cyclin E, a promoter that modu-
lates the transition from the G1 to S phase and accelerates 
cell cycle progression through the G1 phase. Malignant 
cells blocked in the G2/M phase are more vulnerable to ra-
diation, which implies the G2/M phase retardation of cancer 
cells regulated by glucose-Au nanoparticles would be killed 
effectively during subsequent radiotherapy. Because cancer 
cells are more sensitive to cell cycle disruption and DNA 
damage than healthy ones, Au nanoparticles that induce 
such effects can be selectively delivered to malignant cells 
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to help destroy them.  
Although most Au nanoparticles are preferentially trans-
located into the endosome/lysosome because of their larger 
relative sizes, Au nanoparticles can also be conjugated to 
specific peptide sequences to actively target different orga-
nelles or the nucleus in the cell. The El-Sayed group [66] 
developed novel Au nanospheres conjugated to two differ-
ent peptides, arginine-glycine-aspartic acid (RGD) and nu-
clear localization sequence (NLS), which recognize alpha V 
beta integrins on the cancer cell surface and cytoplasmic 
importins located near the nuclear pore complex, respec-
tively. Using time-resolved dark-field scattering microscopy, 
they observed distinct cytokinesis arrest in squamous carci-
noma cell line HSC-3 after 24 h incubation with the Au 
nanosphere conjugates. Neither non-malignant cell line 
HaCaT or nanoparticles conjugated to the RGD peptide 
only (without NLS) induced a similar phenomenon, indi-
cating the specific pathological process as a result of Au 
nanospheres accumulating in the nucleus of the cancer cells. 
Subsequently, the group studied the cancer cells that un-
derwent cytokinesis arrest by immunofluorescence micros-
copy and found a significant number of breaks in the dou-
ble-stranded DNA. Flow cytometry also confirmed 20% 
more apoptosis in malignant cells than non-malignant ones 
when both were treated with RGD/NLS particles. Thus, the 
selective and anti-proliferative properties of targeted nano-
particle conjugates could, in the future, serve in anti-cancer 
treatments functionally analogous to current radiotherapy 
and chemotherapy methods.    
3.3  Au nanoparticles as drug delivery vehicles 
Like most nanocarriers, Au nanoparticles possess several 
advantages when serving as drug delivery vehicles. The 
enhanced permeability and retention effect [69] of Au na-
noparticles allows them to preferentially accumulate at tu-
mor sites because tumors possess leaky blood vessels. Fac-
ile bioconjugation can be realized at the particle surface 
because of the strong binding affinity of Au nanoparticles 
for thiols, which allows Au nanoparticles to be easily func-
tionalized with antibodies and biomolecules such as folate 
to achieve active targeting. In addition, the unique optical 
properties of Au nanoparticles favor them as latent photo-
thermal agents in most cases, indicating the possibility of 
combinational therapeutics in one treatment. 
Very recently, we developed novel mesoporous sili-
ca-coated Au nanorods (Au@SiO2) as a multifunctional 
therapeutic platform [70]. The outer mesoporous SiO2 shell 
provided a large surface area for doxorubicin (DOX) pay-
load, which made up for the limited capacity of the Au na-
norods as drug carriers (Figure 6A). Notably, the silica shell 
did not alter the SPR maximum of the Au nanorods, so a 
tissue-penetrating NIR laser could be employed for irradia-
tion. In vitro drug release experiments showed that 50% of 
loaded DOX escaped from Au@SiO2 within 12 h following 
laser irradiation (250 mW, 780 nm), whereas less than 5% 
was released in the control experiment (Figure 6B). Unex-
pectedly, 5–10-fold increases in the uptake of DOX when 
loaded into Au@SiO2 compared with that of free DOX was 
observed in A549 (Figure 6C). Inductively coupled plasma 
mass spectrometry experiments also confirmed effective 
time/dose-dependent accumulation of Au@SiO2 within the 
cells (unpublished data). The positive zeta potential of the 
Au@SiO2-DOX mechanism might partly account for this 
phenomenon. Subsequently, the cytotoxicity of Au@SiO2-       
DOX in A549 was assessed. As expected, Au@SiO2-DOX 
was obviously less toxic than free DOX in the absence of 
laser irradiation because of limited drug release. Two-       
photon confocal microscopy further confirmed the localiza-
tion of most nanoparticles in the endosome/lysosome, thus 
hyperthermia-induced drug release and lysosome destruc-
tion were expected to promote complete drug distribution 
within the cell. Following laser irradiation (3 min, 24 and 48 
W cm2), both lysosomal membrane disruption and cell 
death were observed at high power density (48 W cm2) but 
not at 24 W cm2. As a result, the lower power density (24 
W cm2) was chosen to explore the chemotherapeutic po-
tential of Au@SiO2-DOX and avoid hyperthermia-induced 
cell death. Interestingly, although no cell death was ob-
served in all groups immediately (3 min) after laser irradia-
tion, Au@SiO2-DOX-treated cells showed slight/severe cy-
totoxic effects 12/24 h post irradiation, whereas Au@SiO2- 
treated cells still maintained full viability (Figure 6D). This 
result correlates well with the process of drug release rather 
than hyperthermia-induced cell death because the latter 
would only lead to acute cell killing via instant denaturation 
of biomolecules (proteins, lipids, and nucleotides) caused 
by rapid temperature elevation. Overall, a successful drug 
delivery system was developed using Au nanorods coated 
with mesoporous silica. High drug payload, light-activated 
controlled release and hyperthermia are three distinct ad-
vantages of this novel silica-Au nanocomplex.  
To date, the diverse functional possibilities of Au nano-
particles have inspired a variety of approaches for drug de-
livery system design. Because elemental Au nanostructures 
differ in many aspects (e.g., size, shape, and surface chem-
istry) compared with classical organic drug carriers, devel-
oping novel drug loading/releasing strategies is essential for 
their application as drug delivery vehicles. As summarized 
in an excellent review by Dreaden et al. [45], the loading 
pattern applied to Au nanoparticles has been categorized 
into five classes as follows: (i) Loading by partitioning. Use 
the mono/bilayer structure capping the Au nanoparticle sur-
face (e.g., CTAB) as an organic solvent to partition hydro-
phobic drugs from the surrounding medium. (ii) Loading by 
surface coordination. Employ the binding affinity of thiols 
and amines with the Au surface to attach drugs containing 
such groups via the formation of Au-S or Au-N bonds. (iii) 
Loading by attachment to capping agent. Couple drugs to 
the terminal functional group of capping agents at the  
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Figure 6  Mesoporous silica-coated Au nanorods (Au@SiO2) developed as novel drug carriers for the delivery of DOX in vitro. A, TEM images of Au 
nanorods (left), and Au@SiO2 (right). B, DOX release profiles from Au@SiO2-DOX triggered by NIR laser irradiation at different pH. C, Cellular uptake of 
DOX and Au@SiO2-DOX quantified by flow cytometry. D, Live-dead staining of A549 cells 12 and 24 h post laser irradiation. A549 cells were treated with 
Au@SiO2 or Au@SiO2-DOX for 12 h and then radiated for 3 min using a NIR laser with a power density of 24 W cm
−2. Reproduced with permission from  
ref. [70]. 
outermost layer of Au nanoparticles, especially those Au 
nanoparticles already passivated with various functional 
groups. (iv) Loading by layer-by-layer assembly. Takes 
advantage of the highly charged surface of Au nanoparticles 
caused by the presence of charged capping agents to 
achieve the attachment of oppositely charged substances 
(e.g., cationic Au nanoparticles that are positively charged 
versus DNA or siRNA that are negatively charged). (v) 
Loading inside the nanoparticles. Design nanostructures that 
possess internal reservoirs, such as Au nanocages and hol-
low Au nanoshells, to load drugs. 
By employing the strategies listed above, several thera-
peutics have been successfully delivered by Au nanoparti-
cles in cancer treatment, including receptor-targeted mole-
cules (e.g., TNF- [71], and tamoxifen [72]), classical cy-
totoxic agents (e.g., cisplatin [73], oxyplatin [74], DOX [75], 
paclitaxel [76] and MTX [77]) and photosensitizer mole-
cules [78]. By conjugating TNF- to spherical Au nanopar-
ticles with a diameter of 26 nm, Paciotti and co-workers [71] 
observed 7–10-fold greater tumor accumulation of TNF- 
in a mouse model administered with the nanoparticle con-
jugates versus the equivalent mass of protein. The assembly 
of TNF- within tumors induced complete tumor regression 
in 25%–30% of treated mice, which is twice as effective as 
TNF- alone. Systemic toxicity was also reduced because 
no death was observed in THF- conjugate-treated mice  
while 15% mortality was observed after treatment with 
TNF-α alone. Mirkin et al. [73] used the same spherical Au 
nanostructures of smaller size (13 nm in diameter), to load a 
prodrug form of the widely administered chemotherapeutic, 
cisplatin. By conjugating the inert Pt4+ analog of cisplatin 
(Pt2+) to Au nanoparticles, efficient delivery of the prodrug 
into the cytoplasm was achieved in prostate cancer cells 
without endosome sequestration. Subsequent intracellular 
reduction of the prodrug caused activation to the cytotoxic 
Pt2+ form, resulting in colocalization of the particles with 
microtubules and the formation of intrastrand crosslinked 
nuclear DNA. In vitro cytotoxicity was dramatically en-
hanced over that of the free prodrug, demonstrating that Au 
nanoparticles are efficient vehicles for the delivery of pro-
drugs with poor cellular uptake. Targeted delivery of pho-
tosensitizer molecules using Au nanoparticles for photody-
namic therapy (PDT) is another strategy for the selective 
treatment of malignant tissues. In PDT, molecules that gen-
erate singlet oxygen upon excitation need to be selectively 
delivered to malignant tissues and activated by exposure to 
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laser radiation. Burda and co-workers [78] studied the de-
livery of phthalocyanine photosensitizers to cervical cancer 
cells in vitro using PEGylated Au nanoparticles with a di-
ameter of 5 nm. Interestingly, they found that the efficiency 
of particle delivery and PDT was superior when using labile 
amino linkages versus stronger thiol bonds between the na-
noparticles and phthalocyanine, highlighting the signifi-
cance of bonding interactions on subsequent treatment effi-
cacy. 
As mentioned above, the charged surface of Au nanopar-
ticles is an ideal vehicle for the attachment of therapeutics 
carrying the opposite charge [44]. Thus, Au nanoparticles 
are considered to be a perfect candidate for gene delivery. 
Recently, we evaluated the capacity of different positively 
charged coating agents, including CTAB, PDDAC and pol-
yethylenimine (PEI), on DNA adsorption and cellular 
transfection using Au nanorods [79]. Interestingly, the three 
coating agents exhibited similar DNA adsorption efficien-
cies ranging from 40%–60%, but varied in transfection per-
formance in HEK293 cells. 48 h post transfection, bright 
fluorescence was observed from cells treated with PDDAC- 
and PEI-coated nanorods but not CTAB-coated ones (na-
norods were carrying plasmid encoding enhanced green 
fluorescent protein as an indicator). Notably, the fluores-
cence intensity from cells treated with PDDAC- and 
PEI-coated nanorods treated cells was as high as that from 
commercial transfection agent-PEI treated cells. Subsequent 
nucleus localization experiments gave similar results. DNA 
delivered by PDDAC and PEI-coated nanorods was present 
in the nucleus as early as 2.5 h post transfection, whereas 
CTAB-coated nanorods produced comparable results after 
more than 5 h. In this case, Au nanorods coated with posi-
tively charged capping agents were an effective means to 
deliver DNA to both the cytoplasm and nucleus of cells. 
Novel anti-cancer vaccines could be developed by using Au 
nanoparticles as tumor-associated antigen carriers. 
4  Conclusion and perspective 
Au nanoparticles are a large family of nanostructures de-
rived from different chemical conditions. The tremendous 
diversity of Au nanoparticles has raised a number of possi-
bilities for their design in treating cancer from different as-
pects. As illustrated in this review, a growing body of evi-
dence has already revealed the huge theranostic potential of 
Au nanoparticles in serving as (i) photothermal contrast 
agents, (ii) imaging contrast agents, (iii) drug/gene delivery 
vehicles and (iv) intrinsic anti-cancer agents. Although the 
success achieved so far is very encouraging, there are still 
several important questions that need to be clarified. Bio-
compatibility is the first and most important issue. To date, 
the majority of data obtained from published articles sug-
gests Au nanoparticles show low toxicity in experimental 
systems. However, in most cases toxicity assays were con-
ducted on either cultured cell monolayers or living animals 
for a short term. Thus, systemic evaluation of toxicity with 
an additional focus on the long-term effects of Au nanopar-
ticles on human health is critical for their future application 
in medicine [80]. Another important question is the actual 
therapeutic efficacy of Au nanoparticles in clinical treat-
ment. In most studies, the experiment model is highly spe-
cific (e.g., the selectivity of ligand-conjugated nanoparticles 
is always tested on a specific cell line with abundant recep-
tors), which means the same results may not be achieved 
under general conditions. Therefore, despite their vast po-
tential in cancer therapy, further effort is needed to acquire 
detailed information that will promote the development of 
Au nanoparticles for clinical applications. 
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